National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2

详细信息    查看全文

• 作者：Terry A. Jacobson ; MD^a ; ^{tjaco02@emory.edu" class="auth_mail" title="E-mail the corresponding author} ; Kevin C. Maki ; PhD^b ; Carl E. Orringer ; MD^c ; Peter H. Jones ; MD^d ; Penny Kris-Etherton ; PhD^e ; Geeta Sikand ; MA^f ; Ralph La Forge ; MSc^g ; Stephen R. Daniels ; MD ; PhD^h ; Don P. Wilson ; MDⁱ ; Pamela B. Morris ; MD^j ; Robert A. Wild ; MD ; PhD ; MPH^k ; Scott M. Grundy ; MD ; PhD^l ; Martha Daviglus ; MD ; PhD^m ; Keith C. Ferdinand ; MDⁿ ; Krishnaswami Vijayaraghavan ; MD^o ; Prakash C. Deedwania ; MD^p ; Judith A. Aberg ; MD^q ; Katherine P. Liao ; MD ; MPH^r ; James M. McKenney ; PharmD^s ; Joyce L. Ross ; MSN ; CRNP^t ; Lynne T. Braun ; PhD ; CNP^u ; Matthew K. Ito ; PharmD^v ; Harold E. Bays ; MD^w ; W. Virgil Brown ; MD^x ; On behalf of the NLA Expert Panel
• 关键词：Clinical recommendations ; Dyslipidemia ; Lifestyle therapies ; Children ; Elderly ; Human immunodeficiency virus ; Rheumatoid arthritis ; Residual risk ; Adherence ; Team-based care
• 刊名：Journal of Clinical Lipidology
• 出版年：2015
• 出版时间：November-December 2015
• 年：2015
• 卷：9
• 期：6_supp_S
• 页码：S1-S122.e1
• 全文大小：5755 K

文摘

An Expert Panel convened by the National Lipid Association previously developed a consensus set of recommendations for the patient-centered management of dyslipidemia in clinical medicine (part 1). These were guided by the principle that reducing elevated levels of atherogenic cholesterol (non–high-density lipoprotein cholesterol and low-density lipoprotein cholesterol) reduces the risk for atherosclerotic cardiovascular disease. This document represents a continuation of the National Lipid Association recommendations developed by a diverse panel of experts who examined the evidence base and provided recommendations regarding the following topics: (1) lifestyle therapies; (2) groups with special considerations, including children and adolescents, women, older patients, certain ethnic and racial groups, patients infected with human immunodeficiency virus, patients with rheumatoid arthritis, and patients with residual risk despite statin and lifestyle therapies; and (3) strategies to improve patient outcomes by increasing adherence and using team-based collaborative care.